Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab with Chemoradiation for Resectable Esophageal/GE Cancer
NCT03490292Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- May 2018
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in esophageal cancer, gastroesophageal junction cancer, sponsored by University of Wisconsin–Madison. Started May 2018; status: completed.
02
Drugs
avelumab
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03490292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03490292.